Precipio Product Revenue Jumps 40% in Third Quarter to $1.010 Million
Key Facts
Precipio said net sales in the third quarter of 2026 rose 8% to $7.331 million from $6.767 million in the same period of 2025, according to its filing with the U.S. Securities and Exchange Commission. The increase came as product and diagnostic services revenue grew, while the non-GAAP Adjusted EBITDA measure fell. The company reported a net loss of $8,000 for the quarter, compared with $79,000 a year earlier. The chief executive said the company achieved "record revenue while maintaining positive Adjusted EBITDA and generating cash from operations." The results show revenue growth and an improvement in net loss, but coincided with a decline in Adjusted EBITDA and the company's disclosure of substantial doubt about its ability to continue as a going concern.
Product revenue was the main source of growth, rising 40% to $1.010 million from $721,000 in the third quarter of 2025. The company attributed the increase mainly to revenue from new product projects and activities unrelated to historical product sales. On a quarterly basis, product revenue was $1.0 million in the third quarter, compared with $0.9 million in the second quarter of 2026, according to the results statement. The company said the revenue included new projects, without attributing its growth to another source. Total sales were $7.3 million for the quarter, compared with $7.0 million in the previous quarter, according to the statement.
Net diagnostic services revenue, after the allowance for credit losses, rose 5% to $6.321 million in the third quarter from $6.046 million in the same period a year earlier. Precipio processed 4,582 diagnostic cases during the quarter, up 8% from 4,258 cases in the third quarter of 2025. The company said growth in case volume was partly offset by a lower average revenue per case. It attributed that to differences in the mix of case types processed during the period. Gross profit was $3.378 million, compared with $3.005 million a year earlier, while the gross margin rose to 46% from 44%.
The improvement did not extend to every performance measure; Adjusted EBITDA was about $0.4 million in the third quarter, down from $0.5 million a year earlier, although it remained positive, according to the company statement. By contrast, the quarterly net loss narrowed to $8,000 from $79,000. For the first nine months of 2026, the operating loss was $2.025 million, compared with $1.744 million in the same period of 2025. That puts the quarterly net loss alongside a larger operating loss for the nine-month period. It also distinguishes net loss from Adjusted EBITDA, which the company described as a non-GAAP measure.
The company said cash flow from operations was about $0.6 million in the third quarter and total cash increased by $0.5 million to a balance of more than $3.5 million at quarter-end. Working capital rose to $3.062 million on September 30, 2026, from $2.287 million on December 31, 2025. But the filing with the Securities and Exchange Commission said substantial doubt exists about the company's ability to continue as a going concern for the twelve months following the issuance of the financial statements. The company linked its ability to continue to executing its business plan and generating additional revenue, while noting that additional financing may be needed. It said positive operating cash flow benefited largely from $1.2 million in nonrecurring employee retention credit payments.
The chief executive said that having more than $3.5 million in cash at quarter-end positions the company, in its view, to accelerate commercialization of its existing product portfolio. The company held a call to update shareholders on third-quarter performance on November 10, 2026, at 5 p.m. Eastern time, including a question-and-answer session. PRPO shares closed at $22.13 on November 13, 2026, according to EL7's daily closing data. The closing price indicates the stock's level on that date, while its trading range during the session was not established. The company's product commercialization plan, execution of its business plan and generation of additional revenue remain among the factors it said are tied to its ability to continue as a going concern for the twelve months following the issuance of the financial statements.